Neurobiological early diagnosis of Alzheimer's disease

被引：2

作者：

Hampel, H. ^{[1
]}

Teipel, S. J.

Buerger, K.

机构：

[1] Univ Dublin Trinity Coll, AMiNCH, Sch Med, Trinity Ctr Hlth Sci,Discipline Psychiat, Dublin 24, Ireland

[2] Univ Dublin Trinity Coll, AMiNCH, Trinity Ctr Hlth Sci, Trinity Coll Inst Neurosci, Dublin, Ireland

[3] Univ Munich, Alzheimer Gedachtniszentrum, Forsch Grp Dementielle Erkrankungen & Bildgebende, Klin & Poliklin Psychiat & Psychotherapie, Munich, Germany

来源：

NERVENARZT | 2007年 / 78卷 / 11期

关键词：

Aizheimer's disorders; amyloid beta peptide; biological markers; CSF; hippocampus volumetry; mild cognitive impairment; neuroimaging; early diagnosis; Tau protein; total brain volumetry;

D O I：

10.1007/s00115-007-2317-x

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

In order to improve diagnosis of Alzheimer's disease (AD), candidate biological markers in CSF as well as structural and functional imaging were investigated. Biomarkers are clearly needed to support detection of incipient AD in subjects with mild cognitive impairment (MCI). To date the most promising core candidate markers are total and hyperphosphorylated tau protein and amyloid beta peptides in the CSF, as well as hippocampus and whole brain volumetry using MRI. None of the candidates has been finally validated and established for clinical routine so far. International controlled multicenter cooperative studies are ongoing to further develop these core diagnostic marker candidates (phase III). The core markers are reviewed in detail. Promising novel approaches are discussed.

引用

页码：1310 / +

页数：8